Navigation Links
TrialNetworks Customer Steve Sweeney of Arteaus Therapeutics Encourages Clinical Trial Sponsors to Treat Investigative Sites Like Customers by Using Innovative Technology
Date:1/10/2014

Needham, MA (PRWEB) January 10, 2014

Platforms like TrialNetworks’ unique Clinical Trial Optimization System can be used by pharmaceutical companies to improve sponsor-site relations, says TrialNetworks client Steven P. Sweeney, Vice President and Head of Clinical Development Operations for Arteaus Therapeutics, in a new article published by the Journal for Clinical Research Best Practices.

The article, “Treat Your Sites Like Customers... and Use Technology to Help Do It,” examines the cost of poor sponsor-site relationships and urges sponsors to change their mindset and fix communication problems. Steve says that sponsors can leverage solutions such as the exclusive TrialNetworks platform to keep sites engaged through consistent communication strategies, online training apps, helpful visit guides, support tools, and more. Topics covered include:

  •     How to assess your current communication practices
  •     An overview of clinical trial portals and communication platforms
  •     Functions that can be improved by such technology
  •     Site adoption case study during a 13-month trial

TrialNetworks Co-Founder and CEO Eric Silberstein said, “Steve Sweeney is a visionary clinical research executive with whom we have had the pleasure of working for several years on multiple trials. We share his passion for site advocacy and his belief that technology platforms like ours help innovative sponsors improve site communications and relationships. We admire and congratulate him for sharing his experiences and advice on how to radically improve clinical trial operations in this important article.”

To discover how the TrialNetworks platform is revolutionizing clinical trial optimization, request a demo at http://www.trialnetworks.com.

About TrialNetworks
TrialNetworks, co-founded by U.S. Surgeon General nominee Dr. Vivek Murthy, provides sponsors and CROs the industry's only Clinical Trial Optimization System. Using this modern and intuitive technology, customers such as Merck & Co., Biogen Idec and Infinity Pharmaceuticals are able to transform the quality and efficiency of clinical operations at each stage of a trial from feasibility through closeout. TrialNetworks apps, including Checklist™, Training™, Document Library™, Visit Guide™, Action Items™ and Directory™, are available in a unified and secure cloud-based interface.

Customers ranging from biotechs to Top-10 pharma companies have implemented the TrialNetworks platform for use in Phase I-IV trials by more than 25,000 site staff in 60 countries. To learn why sponsors and CROs rely on TrialNetworks to optimize clinical trial operations, request a guided online demo at http://www.trialnetworks.com.

Read the full story at http://www.prweb.com/releases/2014/01/prweb11479184.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. TrialNetworks Customer to Present Results of Using Site Engagement Technology to Improve Study Operations and Patient Enrollment at Clinical Trial Optimization Conference
2. TrialNetworks Feasibility Survey™ App Gets ARIAD Pharmaceuticals Unprecedented 75% Response from Potential Clinical Trial Investigator Sites
3. TrialNetworks Sees Strong Growth in Demand for its Clinical Trial Optimization System as Pharma Seeks Technology to Improve Operations Quality and Efficiency
4. TrialNetworks Co-founder and Chairman Vivek Murthy, MD, MBA, Nominated by President Barack Obama as Surgeon General of the United States of America
5. Customer Satisfaction, A key to Success: Narang Medical Limited
6. TAKE Solutions Brings Together Leading Experts and TAKE Customers at “Converge 2012” to Discuss Business
7. Transportation and Energy Customers Look to Wharfedale’s SAP® Solutions with an Eye toward Cost Savings and Improved Operational Efficiencies
8. Sangui Bio Tech International Inc. - Over 500 Customers: Granulox Sales Ahead of Planning
9. Z Trim Holdings Grows Customer Base
10. BioInformatics LLC Announces New Market Report – Enhancing the Customer Experience: Insights and Life Science Supplier Rankings (13-002)
11. SoundConnect Announces New Not-For-Profit Customer in Smart Card Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Wayne. NJ (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a ... rinse one eye at a time. So which eye do you rinse first if a ... you have Plum Duo Eye Wash with its unique dual eye piece. , ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/10/2017)... ... ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled a ... new look is part of a transformation to increase awareness, appeal to new markets ... It will also expand its service offering from its signature gourmet cooking classes and ...
(Date:10/10/2017)... Oct. 10, 2017 International research firm Parks Associates ... speak at the TMA 2017 Annual Meeting , October 11 in ... the residential home security market and how smart safety and security products ... Parks Associates: Smart ... "The residential security market ...
Breaking Biology Technology:
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):